title: The effect of K-ATP channel blockage during erythropoietin treatment in renal ischemia-reperfusion injury.
abstract: ATP dependent K channels (K-ATP) take part in the Erythropoietin (EPO) induced cardioprotection but these channel activations have role in cytoprotective role of EPO in the renal ischemia reperfusion (IR) damage is still unknown. For this purpose rats were pretreated with EPO (500 IU/kg) and/or K-ATP channel blocker glibenclamide (40 mM/kg) i.p. before bilateral renal IR damage. Renal tissues were used for histological examination and measurement of caspase-3 and TNF-alpha levels. Renal functions were evaluated by glomerular filtration rate (GFR) fractional excretion of sodium (FENa) and potassium (FEK). Renal TNF-alpha and caspase-3 levels were decreased in both glibenclamide and EPO-treated IR rats compared to untreated rats. The protection afforded by the pretreatment with EPO alone was greater than that of administering glibenclamide alone. Application of glibenclamide at the same time partly abolished the cytoprotective effect of EPO treatment. K-ATP mediated cytoprotection is not the main mechanism of protective effect of EPO.
authors.affiliation: Ankara University, Faculty of Medicine, Molecular Biology Research and Development Unite, and Pathophysiology Department, Ankara, Turkey. nurayyazihan@yahoo.com
authors.forename: Nuray
authors.initials: N
authors.lastname: Yazihan
authors.forename: Haluk
authors.initials: H
authors.lastname: Ataoglu
authors.forename: Guzin Ozelci
authors.initials: GO
authors.lastname: Kavas
authors.forename: Nalan
authors.initials: N
authors.lastname: Akyurek
authors.forename: Burcu
authors.initials: B
authors.lastname: Yener
authors.forename: Cengiz
authors.initials: C
authors.lastname: Aydm
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D053148:Caspase 3 / Q000378:metabolism; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000494:pharmacology*; D005919:Glomerular Filtration Rate / Q000187:drug effects; D005905:Glyburide / Q000494:pharmacology; D054086:KATP Channels / Q000037:antagonists & inhibitors*; D007668:Kidney / Q000098:blood supply / Q000187:drug effects* / Q000293:injuries* / Q000473:pathology; D008297:Male; D026902:Potassium Channel Blockers / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins; D015427:Reperfusion Injury / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D054086:KATP Channels; D026902:Potassium Channel Blockers; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D004921:Erythropoietin; D000068817:Epoetin Alfa; C505410:Casp3 protein, rat; D053148:Caspase 3; D005905:Glyburide